Schoneberg T, Yun J, Wenkert D, Wess J
Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA.
EMBO J. 1996 Mar 15;15(6):1283-91.
Inactivating mutations in distinct G protein-coupled receptors (GPCRs) are currently being identified as the cause of a steadily growing number of human diseases. Based on previous studies showing that GPCRs are assembled from multiple independently stable folding units, we speculated that such mutant receptors might be functionally rescued by 'supplying' individual folding domains that are lacking or misfolded in the mutant receptors, by using a co-expression strategy. To test the feasibility of this approach, a series of nine mutant V2 vasopressin receptors known to be responsible for X-linked nephrogenic diabetes insipidus were used as model systems. These mutant receptors contained nonsense, frameshift, deletion or missense mutations in the third intracellular loop or the last two transmembrane helices. Studies with transfected COS-7 cells showed that none of these mutant receptors, in contrast to the wild-type V2 receptor, was able to bind detectable amounts of the radioligand, [3H]arginine vasopressin, or to activate the G(S)/adenylyl cyclase system. Moreover, immunological studies demonstrated that the mutant receptors were not trafficked properly to the cell surface. However, several of the nine mutant receptors regained considerable functional activity upon co-expression with a C-terminal V2 receptor peptide spanning the sequence where the various mutations occur. In many cases, the restoration of receptor activity by the co-expressed receptor peptide was accompanied by a significant increase in cell surface receptor density. These findings may lead to the design of novel strategies in the treatment of diseases caused by inactivating mutations in distinct GPCRs.
目前,不同的G蛋白偶联受体(GPCR)中的失活突变正被确定为越来越多人类疾病的病因。基于先前的研究表明GPCR由多个独立稳定的折叠单元组装而成,我们推测通过共表达策略“提供”突变受体中缺失或错误折叠的单个折叠结构域,可能在功能上挽救此类突变受体。为了测试这种方法的可行性,一系列已知导致X连锁肾性尿崩症的9种突变V2加压素受体被用作模型系统。这些突变受体在第三个细胞内环或最后两个跨膜螺旋中含有无义、移码、缺失或错义突变。对转染的COS-7细胞的研究表明,与野生型V2受体相比,这些突变受体中没有一个能够结合可检测量的放射性配体[3H]精氨酸加压素,或激活G(S)/腺苷酸环化酶系统。此外,免疫学研究表明突变受体不能正确转运到细胞表面。然而,9种突变受体中的几种在与跨越各种突变发生序列的C端V2受体肽共表达后恢复了相当大的功能活性。在许多情况下,共表达的受体肽恢复受体活性伴随着细胞表面受体密度的显著增加。这些发现可能会导致设计出治疗由不同GPCR失活突变引起的疾病的新策略。